515 related articles for article (PubMed ID: 31640913)
21. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
Martin DT; Ghabili K; Levi A; Humphrey PA; Sprenkle PC
Urology; 2019 Mar; 125():64-72. PubMed ID: 30552940
[TBL] [Abstract][Full Text] [Related]
22. Central zone lesions on magnetic resonance imaging: Should we be concerned?
Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
[TBL] [Abstract][Full Text] [Related]
23. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
Hosseiny M; Shakeri S; Felker ER; Lu D; Sayre J; Ahuja P; Raman SS
AJR Am J Roentgenol; 2020 Sep; 215(3):660-666. PubMed ID: 32755166
[No Abstract] [Full Text] [Related]
24. Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study.
Kam J; Yuminaga Y; Krelle M; Gavin D; Koschel S; Aluwihare K; Sutherland T; Skinner S; Brennan J; Wong LM; Louie-Johnsun M
BJU Int; 2019 Aug; 124(2):297-301. PubMed ID: 30714285
[TBL] [Abstract][Full Text] [Related]
25. Effects of "real life" prostate MRI inter-observer variability on total needle samples and indication for biopsy.
Rosenzweig B; Laitman Y; Zilberman DE; Raz O; Ramon J; Dotan ZA; Portnoy O
Urol Oncol; 2020 Oct; 38(10):793.e13-793.e18. PubMed ID: 32303407
[TBL] [Abstract][Full Text] [Related]
26. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.
Radtke JP; Takhar M; Bonekamp D; Kesch C; Erho N; du Plessis M; Buerki C; Ong K; Davicioni E; Hohenfellner M; Hadaschik BA
Eur Urol Focus; 2018 Jul; 4(4):540-546. PubMed ID: 28753844
[TBL] [Abstract][Full Text] [Related]
27. PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.
Woo S; Kim SY; Lee J; Kim SH; Cho JY
Eur Radiol; 2016 Oct; 26(10):3580-7. PubMed ID: 26847042
[TBL] [Abstract][Full Text] [Related]
28. The Impact of Histopathological Features of Prostate Cancerous Lesions on Multiparametric Magnetic Resonance Imaging Findings using PI-RADS Version 2.
Naito H; Kato T; Ishikawa R; Tanaka K; Ueda N; Matsuoka Y; Miyauchi Y; Taoka R; Tsunemori H; Haba R; Nishiyama Y; Sugimoto M; Kakehi Y
Urology; 2021 Mar; 149():174-180. PubMed ID: 33285212
[TBL] [Abstract][Full Text] [Related]
29. Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologists' Training Program?
Luzzago S; Petralia G; Musi G; Catellani M; Alessi S; Di Trapani E; Mistretta FA; Serino A; Conti A; Pricolo P; Nazzani S; Mirone V; Matei DV; Montanari E; de Cobelli O
Clin Genitourin Cancer; 2019 Apr; 17(2):88-96. PubMed ID: 30527286
[TBL] [Abstract][Full Text] [Related]
30. Complementing the active surveillance criteria with multiparametric magnetic resonance imaging.
Kim TU; Baek SR; Song WH; Nam JK; Lee HJ; Park SW
Investig Clin Urol; 2020 Nov; 61(6):573-581. PubMed ID: 33135402
[TBL] [Abstract][Full Text] [Related]
31. Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?
Hoffmann R; Logan C; O'Callaghan M; Gormly K; Chan K; Foreman D
Int Urol Nephrol; 2018 Jan; 50(1):13-19. PubMed ID: 29188489
[TBL] [Abstract][Full Text] [Related]
32. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.
Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M
Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351
[TBL] [Abstract][Full Text] [Related]
33. Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
Morris DS; Woods JS; Edwards B; Lenz L; Logan J; Flake DD; Mabey B; Bishoff JT; Cohen T; Stone S
Urol Oncol; 2021 Jun; 39(6):366.e19-366.e28. PubMed ID: 33257218
[TBL] [Abstract][Full Text] [Related]
34. Contemporary Epstein Criteria with Biopsy-Naïve Multiparametric Magnetic Resonance Imaging to Prevent Incorrect Assignment to Active Surveillance in the PI-RADS Version 2.0 Era.
Fan Y; Zhai L; Meng Y; Chen Y; Sun S; Wang H; Hu S; Shen Q; Liu Y; Li D; Feng X; He Q; Wang X; Yu W; Jin J
Ann Surg Oncol; 2018 Nov; 25(12):3510-3517. PubMed ID: 30225837
[TBL] [Abstract][Full Text] [Related]
35. The Risk of Prostate Cancer Progression in Active Surveillance Patients with Bilateral Disease Detected by Combined Magnetic Resonance Imaging-Fusion and Systematic Biopsy.
Williams C; Khondakar NR; Daneshvar MA; O'Connor LP; Gomella PT; Mehralivand S; Yerram NK; Egan J; Gurram S; Rompré-Brodeur A; Webster BR; Owens-Walton J; Parnes H; Merino MJ; Wood BJ; Choyke P; Turkbey B; Pinto PA
J Urol; 2021 Nov; 206(5):1157-1165. PubMed ID: 34181465
[TBL] [Abstract][Full Text] [Related]
36. Minimum Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective, Lesion Based Analyses of Patients Treated with Radical Prostatectomy.
Leyh-Bannurah SR; Kachanov M; Beyersdorff D; Tian Z; Karakiewicz PI; Tilki D; Fisch M; Maurer T; Graefen M; Budäus L
J Urol; 2020 Feb; 203(2):299-303. PubMed ID: 31483694
[TBL] [Abstract][Full Text] [Related]
37. Comparing Prostate Imaging-Reporting and Data System Version 2 (PI-RADSv2) Category 1 and 2 Groups: Clinical Implication of Negative Multiparametric Magnetic Resonance Imaging.
Kim JK; Lee HJ; Hwang SI; Choe G; Hong SK
Biomed Res Int; 2020; 2020():2819701. PubMed ID: 32337234
[TBL] [Abstract][Full Text] [Related]
38. Role of PI-RADSv2 with multiparametric MRI in determining who needs active surveillance or definitive treatment according to PRIAS.
Park JJ; Park BK
J Magn Reson Imaging; 2017 Jun; 45(6):1753-1759. PubMed ID: 27783436
[TBL] [Abstract][Full Text] [Related]
39. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
40. Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.
Voss J; Pal R; Ahmed S; Hannah M; Jaulim A; Walton T
BJU Int; 2018 Jun; 121(6):863-870. PubMed ID: 29239082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]